Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.

Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ.

PLoS Pathog. 2007 Feb;3(2):e25.

2.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

3.

Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.

Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E.

J Virol. 2005 Sep;79(18):11627-37.

4.

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH.

J Virol. 2005 Nov;79(22):14161-8.

5.

Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Adams WC, Bond E, Havenga MJ, Holterman L, Goudsmit J, Karlsson Hedestam GB, Koup RA, Loré K.

J Gen Virol. 2009 Jul;90(Pt 7):1600-10. doi: 10.1099/vir.0.008342-0. Epub 2009 Mar 12.

PMID:
19282435
6.

A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Gayle RB, Amalfitano A, Jones FR.

Immunol Lett. 2009 Jan 29;122(1):44-51. doi: 10.1016/j.imlet.2008.11.003. Epub 2008 Dec 13.

7.

Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunity.

Aldhamen YA, Seregin SS, Schuldt NJ, Rastall DP, Liu CJ, Godbehere S, Amalfitano A.

J Immunol. 2012 Aug 1;189(3):1349-59. doi: 10.4049/jimmunol.1200736. Epub 2012 Jun 27.

8.

Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, Hayakawa T.

J Virol. 2003 Dec;77(24):13062-72.

9.

Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Loré K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA.

J Immunol. 2007 Aug 1;179(3):1721-9.

10.

Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M, Einfeld D, Schwartz RM, King CR, Gall JG, Nabel GJ.

J Virol. 2009 Jul;83(14):7166-75. doi: 10.1128/JVI.00374-09. Epub 2009 May 6.

11.

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2005 Aug;79(15):9694-701.

12.

Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.

Cheng C, Gall JG, Nason M, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR, Duerr AC, Keefer MC, Graham BS, Nabel GJ.

J Virol. 2010 Jan;84(1):630-8. doi: 10.1128/JVI.00866-09. Epub .

13.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63. Epub 2007 Feb 28.

15.

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, Osterhaus AD, Havenga MJ.

Vaccine. 2004 Aug 13;22(23-24):3035-44.

PMID:
15297053
16.

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R.

J Immunol. 2001 Apr 15;166(8):5236-44.

17.

Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines.

Rozis G, de Silva S, Benlahrech A, Papagatsias T, Harris J, Gotch F, Dickson G, Patterson S.

Eur J Immunol. 2005 Sep;35(9):2617-26.

18.

Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors.

Nakamura T, Sato K, Hamada H.

Hum Gene Ther. 2002 Mar 20;13(5):613-26.

PMID:
11916485
19.

In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity.

Hsu C, Boysen M, Gritton LD, Frosst PD, Nemerow GR, Von Seggern DJ.

Virology. 2005 Feb 5;332(1):1-7.

20.

Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.

Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R.

J Gen Virol. 2006 Sep;87(Pt 9):2487-95.

PMID:
16894186
Items per page

Supplemental Content

Write to the Help Desk